{"product_id":"ew-business-model-canvas","title":"Edwards Lifesciences Corporation (EW): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a clear, research-based view of Edwards Lifesciences Corporation's business, showing how it creates value through minimally invasive structural heart therapies, durable valve technologies, and strong clinical evidence. You'll see the core partners, activities, and resources behind the model, including FDA and global regulators, hospitals and heart teams, clinical trial investigators, transcatheter valve R\u0026amp;D, pivotal trials, manufacturing, the \u003cstrong\u003eSAPIEN\u003c\/strong\u003e, \u003cstrong\u003eEVOQUE\u003c\/strong\u003e, and \u003cstrong\u003eSAPIEN M3\u003c\/strong\u003e platforms, and the \u003cstrong\u003eRESILIA\u003c\/strong\u003e tissue portfolio, plus the main customer groups, channels, costs, and revenue streams from TAVR, TMTT, surgical heart valves, and international structural heart sales.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eEdwards Lifesciences Corporation's key partnerships center on \u003cstrong\u003eU.S. and global regulators, reimbursement agencies, hospitals, heart teams, clinical investigators, and acquired innovation teams\u003c\/strong\u003e. These partners shape product approval, payment, clinical adoption, and the speed at which new structural heart therapies reach patients.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePartnership type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness model impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA and global regulators\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval of EVOQUE tricuspid valve replacement system\u003c\/td\u003e\n \u003ctd\u003eRegulatory clearance drives launch timing and global commercialization\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS and reimbursement bodies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e Medicare national coverage for transcatheter edge-to-edge repair expanded to include patients at intermediate surgical risk\u003c\/td\u003e\n \u003ctd\u003eCoverage decisions affect patient access and hospital economics\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and heart teams\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e cardiac surgeons were required in earlier CMS TAVR coverage rules\u003c\/td\u003e\n \u003ctd\u003eCenter capability and team structure affect procedure volume and adoption\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial investigators\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of pivotal trials depend on site enrollment, follow-up, and endpoint adjudication\u003c\/td\u003e\n \u003ctd\u003eTrials generate evidence for approval, reimbursement, and guideline use\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired innovation teams\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e announced value for JenaValve Technology acquisition in 2024\u003c\/td\u003e\n \u003ctd\u003eAcquisitions add technology, talent, and development programs\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA and global regulators\u003c\/strong\u003e are a core partnership because Edwards Lifesciences Corporation sells implantable and procedure-dependent devices that cannot scale without approval. The FDA's 2024 approval of EVOQUE created a new regulatory path for tricuspid valve replacement in the United States. For a company built on structural heart therapies, each approval converts clinical data into commercial access. Regulators outside the United States matter the same way because country-by-country approvals determine launch sequencing, labeling, and manufacturing planning.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval of EVOQUE tricuspid valve replacement system\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e regulatory decision can open or delay access across an entire hospital network\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of commercial launch plans depend on local approval status\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCMS and reimbursement bodies\u003c\/strong\u003e matter because payment determines whether hospitals can afford to offer the procedure. For high-cost transcatheter therapies, coverage policy is as important as approval. CMS coverage rules directly shape patient access, hospital margins, and case selection. When reimbursement expands, hospitals are more willing to build programs, train staff, and buy the device inventory needed for repeated procedures.\u003c\/p\u003e\n\n\u003cp\u003eFor academic work, CMS is not just a payer. It is part of the market design. A device can be approved by the FDA and still have weak adoption if payment is too limited. That is why reimbursement policy is a separate partnership in the business model, not a side issue.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e Medicare coverage expansion for transcatheter edge-to-edge repair to intermediate surgical risk patients\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$0\u003c\/strong\u003e in practical market value if hospitals cannot obtain payment approval\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e reimbursement rule can shift national procedure volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and heart teams\u003c\/strong\u003e are the operating unit that turns Edwards Lifesciences Corporation's products into revenue. These teams include interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, and catheterization lab staff. Their adoption matters because Edwards Lifesciences Corporation's devices are not consumer products; they are sold into a workflow that depends on training, procedural competence, patient selection, and follow-up care.\u003c\/p\u003e\n\n\u003cp\u003eHeart team coordination is especially important in structural heart care. A hospital may have FDA approval and CMS coverage, but without trained staff and a repeatable protocol, procedure volume stays low. That makes hospital relationships a practical partnership, not a branding exercise.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e cardiac surgeons were part of earlier CMS TAVR coverage requirements\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e hospital program can include multiple clinical specialties\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of implantation success depends on procedural execution inside the hospital\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trial investigators\u003c\/strong\u003e are essential because Edwards Lifesciences Corporation relies on evidence to win approval, reimbursement, and physician trust. Investigators recruit patients, collect follow-up data, and help define outcomes such as mortality, rehospitalization, valve durability, and quality of life. In structural heart disease, randomized trials and registries are not optional; they are the evidence base that supports adoption.\u003c\/p\u003e\n\n\u003cp\u003eThese partnerships also reduce commercial risk. A device with strong clinical data faces a lower barrier in guideline discussions and hospital credentialing. That matters because physician buyers in this market are evidence-driven and often compare outcomes across competing devices.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e pivotal trial can support both approval and reimbursement\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e months is a common minimum follow-up period in cardiovascular device studies\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of endpoint data quality depends on investigator compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquired innovation teams\u003c\/strong\u003e matter because Edwards Lifesciences Corporation uses acquisitions to add technologies and people that can be integrated into its commercial and research platform. The 2024 announced value of the JenaValve Technology acquisition was \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e. That type of transaction gives Edwards Lifesciences Corporation access to external product pipelines and specialized engineering talent without building everything internally from scratch.\u003c\/p\u003e\n\n\u003cp\u003eAcquired teams are a partnership because value depends on retention, integration, and regulatory execution after the deal closes. The acquired team's engineers, clinical specialists, and regulatory staff often hold knowledge that cannot be replicated quickly. For a company in structural heart, speed matters because first-mover advantage can shape physician familiarity and center adoption.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAcquired team item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumber or amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJenaValve Technology acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAdds technology and personnel for tricuspid valve development\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory approval dependency\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e FDA approval can change launch timing\u003c\/td\u003e\n \u003ctd\u003eDetermines when acquired innovation becomes commercial\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical evidence dependency\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e pivotal data package can support market entry\u003c\/td\u003e\n \u003ctd\u003eTurns development work into reimbursable care\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe partnership structure is tightly linked to the economics of structural heart devices. Approval from regulators, payment from CMS and other bodies, adoption by hospitals, data from investigators, and technology from acquisitions all connect to one outcome: whether a new device can move from development into routine care. In this business model, no single partner is enough on its own.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEdwards Lifesciences Corporation\u003c\/strong\u003e builds its business around transcatheter heart valve innovation, large clinical trials, regulatory clearance, and physician adoption. The company's key activities are concentrated in a small number of high-value, highly regulated medical technology tasks that directly shape revenue, growth, and competitive position.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eWhat Edwards Lifesciences Corporation does\u003c\/th\u003e\n \u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eReal-life numbers or amounts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTranscatheter valve R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eDesigns and improves transcatheter heart valves and delivery systems\u003c\/td\u003e\n \u003ctd\u003eCreates new products and expands approved uses\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e in research and development expense in 2024\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal clinical trials\u003c\/td\u003e\n\u003ctd\u003eRuns studies to prove safety and effectiveness\u003c\/td\u003e\n \u003ctd\u003eSupports regulatory approval and physician adoption\u003c\/td\u003e\n \u003ctd\u003eEARLY TAVR enrolled \u003cstrong\u003e901\u003c\/strong\u003e patients\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submissions and approvals\u003c\/td\u003e\n\u003ctd\u003eFiles data with the FDA and other regulators\u003c\/td\u003e\n \u003ctd\u003eAllows commercialization in major markets\u003c\/td\u003e\n \u003ctd\u003eEVOQUE received U.S. FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and quality control\u003c\/td\u003e\n\u003ctd\u003eMakes implantable devices under strict quality systems\u003c\/td\u003e\n \u003ctd\u003eSupports reliability, safety, and supply continuity\u003c\/td\u003e\n \u003ctd\u003e2024 gross margin was \u003cstrong\u003e76.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician training and market access\u003c\/td\u003e\n\u003ctd\u003eTrains clinicians and supports hospital adoption\u003c\/td\u003e\n \u003ctd\u003eDrives procedure growth and reimbursement use\u003c\/td\u003e\n \u003ctd\u003e2024 net sales were \u003cstrong\u003e$5.44 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eTranscatheter valve R\u0026amp;D\u003c\/strong\u003e is the core activity because Edwards Lifesciences Corporation competes on device design, delivery precision, durability, and ease of use. In practical terms, this means engineering valves that can be delivered through a catheter instead of open-heart surgery. That work requires product iteration across valve frames, tissue material, sheath size, imaging compatibility, and delivery control. The business impact is direct: stronger R\u0026amp;D produces products that can win physician preference, expand into new patient groups, and support premium pricing.\u003c\/p\u003e\n\n\u003cp\u003eThe company's R\u0026amp;D spending gives you a clear measure of how central this activity is. In \u003cstrong\u003e2024\u003c\/strong\u003e, Edwards Lifesciences Corporation reported \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e of research and development expense. For a medical device company, that is not a side activity. It is the engine for future product launches and label expansions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePivotal clinical trials\u003c\/strong\u003e are another major activity because regulators and physicians both want evidence from large patient studies before they adopt new heart valve technologies. These studies are expensive, slow, and highly structured, but they are essential in a market where the products sit inside the heart and affect life expectancy and quality of life. The company uses these trials to compare outcomes, test new indications, and show that less invasive procedures can work for different patient risk groups.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEARLY TAVR enrolled \u003cstrong\u003e901\u003c\/strong\u003e patients.\u003c\/li\u003e\n \u003cli\u003eClinical trial results are used to support label expansion and hospital adoption.\u003c\/li\u003e\n \u003cli\u003eTrial design matters because it affects whether a product can move from a narrow use case to broader treatment populations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory submissions and approvals\u003c\/strong\u003e turn clinical evidence into commercial access. Edwards Lifesciences Corporation must file data packages with regulators, respond to questions, and secure approvals before it can sell a device for a specific use. This is a gatekeeping activity, not a routine administrative task. In cardiovascular devices, one approval can open a large new patient segment, while a delay can push revenue growth back by quarters or even years.\u003c\/p\u003e\n\n\u003cp\u003eOne important example is \u003cstrong\u003eEVOQUE\u003c\/strong\u003e, which received U.S. FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e. That approval mattered because it expanded the company's presence in structural heart therapy beyond aortic valve treatment. Regulatory approval is also linked to reimbursement because hospitals are more likely to adopt a product when both the device label and payment pathway are in place.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and quality control\u003c\/strong\u003e are critical because these products are implanted in the heart and must meet tight tolerances. The company needs controlled production processes, inspection systems, lot traceability, and sterilization controls. A single defect can lead to recalls, clinical risk, and reputational damage. High gross margin is one sign that Edwards Lifesciences Corporation combines premium pricing with disciplined manufacturing execution.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e2024\u003c\/strong\u003e, gross margin was \u003cstrong\u003e76.4%\u003c\/strong\u003e. That level tells you the company can convert product sales into gross profit at a high rate, which is common in specialized medical devices with strong intellectual property and complex manufacturing. It also shows why quality control matters: if defect rates rise, margins can fall quickly through scrap, warranty costs, and supply disruptions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician training and market access\u003c\/strong\u003e are the last major activity because medical device sales depend on procedure adoption, not just product availability. Edwards Lifesciences Corporation has to train interventional cardiologists, cardiac surgeons, and hospital teams on device handling, implantation technique, patient selection, and post-procedure follow-up. It also has to support hospitals with economic evidence, coding, and reimbursement materials.\u003c\/p\u003e\n\n\u003cp\u003eThis activity matters because even a clinically strong product can move slowly if doctors are not trained or hospitals cannot justify the economics. In 2024, Edwards Lifesciences Corporation reported \u003cstrong\u003e$5.44 billion\u003c\/strong\u003e in net sales. That number reflects not just product design, but also the company's ability to translate clinical evidence into real-world procedure volume.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eOperating requirement\u003c\/th\u003e\n\u003cth\u003eBusiness effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTranscatheter valve R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eLong development cycles, device engineering, tissue science, iteration\u003c\/td\u003e\n \u003ctd\u003eProduct pipeline growth and differentiation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal clinical trials\u003c\/td\u003e\n\u003ctd\u003ePatient enrollment, endpoints, monitoring, statistical analysis\u003c\/td\u003e\n \u003ctd\u003eEvidence for safety, effectiveness, and label expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submissions and approvals\u003c\/td\u003e\n\u003ctd\u003eFDA filing, review responses, compliance documentation\u003c\/td\u003e\n \u003ctd\u003eCommercial launch authorization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and quality control\u003c\/td\u003e\n\u003ctd\u003eClean production, inspection, sterilization, traceability\u003c\/td\u003e\n \u003ctd\u003eStable supply and protected margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician training and market access\u003c\/td\u003e\n\u003ctd\u003eProctoring, education, reimbursement support\u003c\/td\u003e\n \u003ctd\u003eProcedure growth and hospital adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e R\u0026amp;D expense in 2024 signals sustained investment in new heart valve platforms.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e901\u003c\/strong\u003e patients in EARLY TAVR show the scale of evidence required for structural heart adoption.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval of EVOQUE shows how regulatory milestones convert research into revenue opportunities.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e76.4%\u003c\/strong\u003e gross margin in 2024 reflects pricing power and manufacturing discipline.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$5.44 billion\u003c\/strong\u003e net sales in 2024 show the commercial importance of physician training and market access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, these key activities are best analyzed as a chain: R\u0026amp;D creates the device, clinical trials prove it, regulators allow it, manufacturing delivers it, and physician education turns it into sales. In Edwards Lifesciences Corporation's case, the numbers show that the model depends on heavy upfront investment and strict execution rather than low-cost volume production.\u003c\/p\u003e\n\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEdwards Lifesciences Corporation's key resources are its transcatheter heart valve leadership, proprietary valve platforms, clinical evidence base, intellectual property, and global commercial organization.\u003c\/strong\u003e These resources support its premium pricing, physician adoption, and expansion from aortic valve therapy into tricuspid and mitral repair and replacement.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eKey resource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number or amount\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRISCEND II pivotal trial for EVOQUE\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eProvides randomized clinical evidence for transcatheter tricuspid valve replacement.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePARTNER 3 trial\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,000\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eSupports Edwards Lifesciences Corporation's long-term TAVR evidence base in low-risk aortic stenosis.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVOQUE U.S. regulatory milestone\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarks commercial entry into a new structural heart market.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eTAVR leadership position\u003c\/strong\u003e is a core resource because it combines installed clinical trust, physician familiarity, and procedural scale. Transcatheter aortic valve replacement is still the company's central franchise, and that matters because hospitals tend to standardize around the most proven platform in high-acuity structural heart care. Edwards Lifesciences Corporation built this position over many years, which gives it an advantage in training, follow-up, and reintervention planning. In this business, being first and being widely used are resources in themselves because they create procedural confidence and repeat use.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic value of this resource is not only volume. It also shapes how the company enters adjacent categories. A strong TAVR base gives Edwards Lifesciences Corporation a reference point for heart teams, reimbursement discussions, and hospital contracting. That makes it easier to move into tricuspid and mitral disease, where physicians want evidence, device reliability, and a clear clinical workflow before they switch from surgery or medical therapy.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTAVR leadership gives the company clinical credibility with structural heart teams.\u003c\/li\u003e\n \u003cli\u003eIt supports cross-selling into hospitals that already know the procedure and the brand.\u003c\/li\u003e\n \u003cli\u003eIt lowers adoption friction for adjacent valve therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSAPIEN, EVOQUE, and SAPIEN M3\u003c\/strong\u003e are key product resources because they represent the company's platform approach to structural heart therapy. SAPIEN is the core transcatheter aortic valve family. EVOQUE is Edwards Lifesciences Corporation's transcatheter tricuspid valve replacement system. SAPIEN M3 is the company's mitral valve replacement program. These are not isolated products; they are a set of platforms that reuse core engineering, imaging, delivery, and physician training capabilities across different valves and anatomies.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePlatform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eResource role\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRelevant real-life number or amount\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAPIEN\u003c\/td\u003e\n\u003ctd\u003eTAVR core franchise\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,000\u003c\/strong\u003e patients in PARTNER 3\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVOQUE\u003c\/td\u003e\n\u003ctd\u003eTricuspid valve replacement platform\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e patients in TRISCEND II\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAPIEN M3\u003c\/td\u003e\n\u003ctd\u003eMitral replacement development platform\u003c\/td\u003e\n\u003ctd\u003eClinical development stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eEVOQUE matters because tricuspid regurgitation has been a large untreated structural heart problem, and the device creates a new addressable market for Edwards Lifesciences Corporation. The company's resource is not just the device itself. It is the combination of delivery system design, procedural know-how, and clinical trial execution that made commercial launch possible. The \u003cstrong\u003eFebruary 2024\u003c\/strong\u003e U.S. approval turned that development resource into a revenue opportunity.\u003c\/p\u003e\n\n\u003cp\u003eSAPIEN M3 matters because mitral disease is harder to treat than aortic disease. The mitral valve sits in a more complex anatomy, so device development depends on precise imaging, anchoring, and sealing performance. That makes the engineering platform and the clinical-development organization a major resource, not just the product design. In a case study, you can use this to show how Edwards Lifesciences Corporation turns one core technical capability into several product lines.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRESILIA tissue portfolio\u003c\/strong\u003e is a durable tissue-engineering resource. It supports the company's surgical and transcatheter strategy by aiming to improve resistance to calcification and extend valve performance. That matters because durability is one of the biggest buying criteria in valve replacement. If a tissue platform lasts longer, it can reduce the need for repeat procedures and strengthen physician preference. For academic work, this is a classic example of a technology resource that reinforces both clinical and commercial positioning.\u003c\/p\u003e\n\n\u003cp\u003eThe portfolio also matters strategically because it bridges surgical and transcatheter products. Edwards Lifesciences Corporation can use the same tissue science platform across multiple valve categories, which raises the value of its R\u0026amp;D spending. In business model terms, this lowers duplication and increases reuse of technical know-how. That is a strong resource advantage because it is harder for competitors to copy than a single product feature.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRESILIA tissue supports differentiation on durability.\u003c\/li\u003e\n \u003cli\u003eIt strengthens the company's surgical valve offering.\u003c\/li\u003e\n \u003cli\u003eIt can improve the long-term case for physician adoption in younger patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical data and IP\u003c\/strong\u003e are among the most important resources in structural heart because buyers do not just purchase a device. They purchase evidence that it works safely in real patients. Edwards Lifesciences Corporation's clinical trial record reduces uncertainty for physicians, hospitals, and payers. The company's evidence base includes large randomized programs such as \u003cstrong\u003ePARTNER 3\u003c\/strong\u003e with \u003cstrong\u003e1,000\u003c\/strong\u003e patients and \u003cstrong\u003eTRISCEND II\u003c\/strong\u003e with \u003cstrong\u003e400\u003c\/strong\u003e patients. Those numbers matter because larger, randomized studies generally carry more weight in clinical and reimbursement decisions than small feasibility studies.\u003c\/p\u003e\n\n\u003cp\u003eIntellectual property strengthens that evidence base by protecting the valve design, delivery systems, leaflet materials, and procedural methods. In this industry, IP matters because the product can be copied faster than the clinical reputation can be built. Patents and proprietary know-how help Edwards Lifesciences Corporation defend premium pricing and preserve development returns. In a research paper, you can frame this as a resource that converts scientific knowledge into legal and economic protection.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eClinical asset\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePatient count\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eStrategic use\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePARTNER 3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports low-risk TAVR evidence and adoption.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRISCEND II\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e400\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports transcatheter tricuspid valve replacement launch.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVOQUE approval\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTurns clinical evidence into a commercial asset.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCash and global commercial team\u003c\/strong\u003e give Edwards Lifesciences Corporation the ability to fund long development cycles and sell complex devices across major markets. Cash matters because structural heart innovation is expensive. The company must pay for clinical trials, regulatory work, manufacturing scale-up, and field support before a new platform becomes profitable. A cash-rich balance sheet gives management flexibility to keep investing even when product launches take time.\u003c\/p\u003e\n\n\u003cp\u003eThe global commercial team is equally important because these devices are sold through a high-touch model. Physicians need training, hospital teams need support, and patient selection must be coordinated carefully. That requires a specialized sales and clinical support organization, not a standard consumer-style sales force. Edwards Lifesciences Corporation's global reach is a resource because it helps the company move new products from trial sites into routine clinical practice.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCash supports clinical trials, manufacturing, and launch spending.\u003c\/li\u003e\n \u003cli\u003eThe commercial team supports physician training and hospital adoption.\u003c\/li\u003e\n \u003cli\u003eGlobal coverage helps the company move products from approval to procedure volume.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEdwards Lifesciences Corporation's value proposition is built around high-acuity heart valve care that uses less invasive procedures, has strong clinical evidence, and reaches patients across surgical and catheter-based settings.\u003c\/strong\u003e The most important proof points are the company's leadership in transcatheter aortic valve replacement, its surgical valve franchise, and its move into transcatheter mitral and tricuspid therapies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMinimally invasive structural heart therapies\u003c\/strong\u003e are central to the model because they let physicians treat diseased valves without open-heart surgery in many cases. That matters because structural heart disease patients are often older and higher risk, so reducing procedural burden can change who can be treated. Edwards' portfolio is centered on transcatheter therapy, especially for aortic, mitral, and tricuspid valve disease, which places the company in a segment where clinical adoption depends on catheter-based delivery, imaging, and physician training.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue proposition area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life company evidence\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimally invasive structural heart therapies\u003c\/td\u003e\n \u003ctd\u003eTranscatheter aortic, mitral, and tricuspid therapies\u003c\/td\u003e\n \u003ctd\u003eTargets patients who may not be candidates for open surgery\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDurable surgical and transcatheter valves\u003c\/td\u003e\n \u003ctd\u003eSurgical valve replacement plus transcatheter valve platforms\u003c\/td\u003e\n \u003ctd\u003eCreates a bridge across full-spectrum valve care\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst U.S. transseptal mitral replacement\u003c\/td\u003e\n \u003ctd\u003eFDA approval of the EVOQUE system in 2024 for tricuspid valve replacement\u003c\/td\u003e\n \u003ctd\u003eShows entry into complex right-heart therapy and expands the addressable market\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrong clinical outcomes and evidence\u003c\/td\u003e\n\u003ctd\u003eRandomized and pivotal clinical trial programs used for U.S. and global approvals\u003c\/td\u003e\n \u003ctd\u003eSupports physician adoption, reimbursement, and guideline inclusion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroad access to advanced valve care\u003c\/td\u003e\n\u003ctd\u003eHospital-based and heart-team driven treatment pathways\u003c\/td\u003e\n \u003ctd\u003eHelps scale use across centers with advanced structural heart programs\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDurable surgical and transcatheter valves\u003c\/strong\u003e are the second core promise. Edwards sells both surgical valves and transcatheter systems, so it can serve hospitals that still need open surgical replacement and those that are moving toward catheter-based treatment. This dual position is important because it reduces dependence on a single procedure type. It also gives the company exposure to both early-stage structural heart disease and more advanced disease that needs intervention. For academic analysis, this is a strong example of a company using product breadth to defend share across adjacent clinical categories.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSurgical valve offerings support patients treated through open or minimally invasive surgery.\u003c\/li\u003e\n \u003cli\u003eTranscatheter platforms support catheter-based replacement in the cath lab or hybrid suite.\u003c\/li\u003e\n \u003cli\u003eCoverage across both channels gives hospitals more than one treatment path for valve disease.\u003c\/li\u003e\n \u003cli\u003eThis mix helps reduce the risk of being tied to one reimbursement or one procedure standard.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst U.S. transseptal mitral replacement\u003c\/strong\u003e is a major strategic value proposition because mitral valve disease has been harder to treat with catheter-based systems than aortic valve disease. Transseptal access means the device reaches the mitral valve through the septum between the atria, avoiding open surgery. That is valuable for patients who face high surgical risk and for hospitals that want a less invasive option for complex valve disease. In late 2025, this remains strategically important because mitral and tricuspid therapies are still earlier in commercialization than aortic therapies, so first-mover clinical and regulatory positions matter.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrong clinical outcomes and evidence\u003c\/strong\u003e are part of the product itself, not just a sales message. In structural heart disease, physicians look for mortality, stroke, rehospitalization, valve durability, and symptom improvement before switching practice patterns. Edwards has built its model around trials, registries, and follow-up data, because those data determine adoption and reimbursement. For a student paper, this is a useful example of how evidence becomes part of the value proposition in medtech. The buyer is not just purchasing a device; the buyer is purchasing a documented treatment pathway.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eClinical evidence supports physician confidence in procedure selection.\u003c\/li\u003e\n \u003cli\u003eBetter outcomes data can influence hospital purchasing and heart-team decisions.\u003c\/li\u003e\n \u003cli\u003ePivotal trials matter because they are used in regulatory approval and payer review.\u003c\/li\u003e\n \u003cli\u003eEvidence also supports product upgrades and next-generation valve designs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad access to advanced valve care\u003c\/strong\u003e means Edwards' systems are designed for use in tertiary hospitals and structural heart programs that can treat large volumes of complex patients. The company's value proposition is not only device performance but also the ability to fit into existing hospital workflows, imaging systems, and catheter lab protocols. Access matters because structural heart therapy often requires specialized teams, and adoption depends on whether hospitals can run procedures efficiently and safely. The broader the access, the larger the patient pool that can receive treatment.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAccess driver\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhat it means in practice\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eBusiness effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeart-team care\u003c\/td\u003e\n\u003ctd\u003eCardiologists and surgeons jointly select therapy\u003c\/td\u003e\n \u003ctd\u003eSupports adoption in complex cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital-based delivery\u003c\/td\u003e\n\u003ctd\u003eProcedures are done in specialized centers\u003c\/td\u003e\n \u003ctd\u003eCreates recurring demand from advanced institutions\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCatheter-based procedures\u003c\/td\u003e\n\u003ctd\u003eLess invasive than open surgery\u003c\/td\u003e\n\u003ctd\u003eExpands eligibility for higher-risk patients\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining and workflow support\u003c\/td\u003e\n\u003ctd\u003eTeams need procedural experience and imaging capability\u003c\/td\u003e\n \u003ctd\u003eRaises switching costs once a platform is established\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eFor business model canvas analysis, the value proposition is strongest where clinical need, procedural complexity, and evidence overlap.\u003c\/strong\u003e Edwards does not compete mainly on low price. It competes on device performance, clinical proof, physician trust, and the ability to treat patients who have few good alternatives. That is why minimally invasive therapy, durable valve performance, first-in-market access in select indications, and broad hospital adoption are all part of the same value proposition.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCustomer relationships in Company Name are built around clinicians, hospital teams, and patient access teams, with the strongest ties created through training, clinical evidence, and post-sale support.\u003c\/strong\u003e The model is less about one-time transactions and more about repeated use in high-stakes procedures where physician confidence, hospital workflow, and reimbursement access all affect adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician education and training\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompany Name depends on physician education because its products are used in complex structural heart and critical care settings. Training is aimed at surgeons, interventional cardiologists, anesthesiologists, nurses, and cath lab staff. In this model, education is not a marketing extra; it is part of product use. A physician who is trained faster is more likely to adopt, repeat, and standardize use across a hospital or health system.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining reduces procedural variation.\u003c\/li\u003e\n\u003cli\u003eTraining supports proper device sizing, implantation, and monitoring.\u003c\/li\u003e\n \u003cli\u003eTraining helps hospitals shorten the learning curve for new users.\u003c\/li\u003e\n \u003cli\u003eTraining can support adoption across multiple departments inside one account.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical support teams\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClinical support is a major relationship layer because the buying decision is tied to outcomes, not just price. Company Name's customer relationship structure depends on teams that can support case planning, intra-procedural questions, and follow-up discussion with clinicians. This matters in settings where even small execution errors can affect patient outcomes and hospital economics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship layer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer group\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician education\u003c\/td\u003e\n\u003ctd\u003ePhysicians and clinical staff\u003c\/td\u003e\n\u003ctd\u003eSupports adoption and repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical support teams\u003c\/td\u003e\n\u003ctd\u003eHospitals and procedure teams\u003c\/td\u003e\n\u003ctd\u003eImproves confidence and workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvidence-driven engagement\u003c\/td\u003e\n\u003ctd\u003eClinicians and hospital decision-makers\u003c\/td\u003e\n\u003ctd\u003eLinks product choice to outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term account management\u003c\/td\u003e\n\u003ctd\u003eHealth systems and purchasing groups\u003c\/td\u003e\n\u003ctd\u003eStabilizes demand across accounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement support\u003c\/td\u003e\n\u003ctd\u003eProviders and administrators\u003c\/td\u003e\n\u003ctd\u003eHelps clear coverage and access barriers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eEvidence-driven engagement\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompany Name uses clinical evidence as the core of its customer relationship model. In medical technology, data from studies, registries, and follow-up outcomes often matter more than general promotion. Evidence helps clinicians justify use, supports hospital value committees, and reduces resistance from payers and administrators. This is important because the customer is often a hospital system, but the end user is a physician making a patient-level decision.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEvidence supports clinical credibility.\u003c\/li\u003e\n\u003cli\u003eEvidence helps justify premium pricing in procedure-heavy categories.\u003c\/li\u003e\n \u003cli\u003eEvidence reduces uncertainty for new adopters.\u003c\/li\u003e\n \u003cli\u003eEvidence helps support label expansion and broader use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term account management\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLong-term account management is central because the company sells into hospitals and health systems that repeat purchases over many years. The relationship is account-based, not consumer-based. That means the company must maintain trust with procurement teams, physicians, finance staff, and administrators at the same time. A strong account relationship can increase procedure consistency, share of wallet, and product standardization inside a system.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAccount function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWho is involved\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure support\u003c\/td\u003e\n\u003ctd\u003eClinical users\u003c\/td\u003e\n\u003ctd\u003eSupports day-to-day utilization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial coordination\u003c\/td\u003e\n\u003ctd\u003eHospital buyers\u003c\/td\u003e\n\u003ctd\u003eAligns supply, ordering, and contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining refresh\u003c\/td\u003e\n\u003ctd\u003eNew staff and rotating teams\u003c\/td\u003e\n\u003ctd\u003eKeeps adoption stable over time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssue resolution\u003c\/td\u003e\n\u003ctd\u003eClinical and operational teams\u003c\/td\u003e\n\u003ctd\u003eProtects trust after problems or delays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eReimbursement and access support\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReimbursement support is a practical part of customer relationships because procedure adoption depends on payment pathways. For hospitals, the question is not only whether a device works, but whether it can be used under existing coverage rules and coding structures. Company Name's access support helps clinicians and administrators navigate documentation, patient qualification, and payer requirements. That matters because even a strong clinical product can face slow adoption if reimbursement is uncertain.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess support reduces friction for hospitals.\u003c\/li\u003e\n \u003cli\u003eReimbursement guidance can speed patient treatment decisions.\u003c\/li\u003e\n \u003cli\u003eCoverage clarity helps administrators plan budgets.\u003c\/li\u003e\n \u003cli\u003eDocumentation support lowers administrative burden on care teams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCustomer relationship economics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis relationship model increases switching costs in a non-contractual way. Once a hospital trains staff, standardizes procedures, and builds internal approval pathways, moving to a different supplier becomes harder. The result is stronger retention, more predictable repeat revenue, and better access to clinical decision-makers. In academic work, you can use this as an example of a B2B medical device model where trust, training, and evidence matter as much as product design.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eEdwards Lifesciences Corporation uses a high-touch, physician-led channel model built around hospital purchasing, specialty cardiac centers, clinical evidence, payer access, and a global commercial network. In this business, channels matter because most sales are tied to procedures, hospital approval, and physician preference rather than consumer demand.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary buyer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHow it works\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales to hospitals\u003c\/td\u003e\n\u003ctd\u003eHospitals, cath labs, operating rooms, procurement teams\u003c\/td\u003e\n \u003ctd\u003eField sales teams work directly with hospital decision-makers and clinical teams\u003c\/td\u003e\n \u003ctd\u003eControls product placement, procedure adoption, and recurring account-level sales\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular centers of excellence\u003c\/td\u003e\n\u003ctd\u003eHigh-volume heart programs and specialty physicians\u003c\/td\u003e\n \u003ctd\u003eFocused clinical support, training, and case planning around complex structural heart procedures\u003c\/td\u003e\n \u003ctd\u003eThese centers drive early adoption, surgeon confidence, and referral flow\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical conferences and publications\u003c\/td\u003e\n\u003ctd\u003ePhysicians, researchers, hospital leaders\u003c\/td\u003e\n \u003ctd\u003ePeer-reviewed studies, congress presentations, and medical education shape clinical preference\u003c\/td\u003e\n \u003ctd\u003eEvidence supports trust in procedure outcomes and helps expand the eligible patient pool\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement and access programs\u003c\/td\u003e\n\u003ctd\u003ePayers, hospitals, patients, billing teams\u003c\/td\u003e\n \u003ctd\u003eCoverage support, coding guidance, and access-related education reduce adoption friction\u003c\/td\u003e\n \u003ctd\u003ePayment clarity affects whether hospitals can justify use of the device and related care pathway\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal commercial organization\u003c\/td\u003e\n\u003ctd\u003eHealthcare systems across regions\u003c\/td\u003e\n\u003ctd\u003eRegional sales, clinical specialists, market access staff, and distributor support coordinate local execution\u003c\/td\u003e\n \u003ctd\u003eSupports consistent launch, training, and service delivery across countries and regulatory regimes\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect sales to hospitals\u003c\/strong\u003e is the core channel. Edwards Lifesciences Corporation does not sell like a consumer company; it sells through a clinical and procurement process. The hospital is usually the paying customer, while physicians and care teams influence which device gets used. That means the channel has to do more than take orders. It has to support procedure planning, in-service training, inventory coordination, and post-sale clinical follow-up. This matters because a single hospital can become a repeat account once a product is embedded in the care pathway.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHospital purchasing teams focus on clinical value, procedure volume, and reimbursement.\u003c\/li\u003e\n \u003cli\u003ePhysicians focus on ease of use, patient outcomes, and procedural reliability.\u003c\/li\u003e\n \u003cli\u003eClinical specialists support case preparation and in-the-room use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular centers of excellence\u003c\/strong\u003e are a concentrated channel for structural heart and critical care products. These centers handle higher procedure volumes, more complex patients, and more advanced adoption of new technologies. For Edwards Lifesciences Corporation, these accounts are important because they influence practice patterns beyond a single site. When a center of excellence adopts a device, it can shape physician referrals, training standards, and wider regional use. This channel also reduces commercial waste because resources are focused on high-impact sites instead of broad, low-yield coverage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCenter type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCommercial role\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel value\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-volume structural heart program\u003c\/td\u003e\n\u003ctd\u003eEarly adoption and complex case support\u003c\/td\u003e\n\u003ctd\u003eCreates clinical credibility and reference accounts\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic medical center\u003c\/td\u003e\n\u003ctd\u003eResearch, training, and publication activity\u003c\/td\u003e\n \u003ctd\u003eSupports evidence generation and physician education\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional referral center\u003c\/td\u003e\n\u003ctd\u003ePatient routing and network influence\u003c\/td\u003e\n\u003ctd\u003eExpands procedure volume across an area\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical conferences and publications\u003c\/strong\u003e are a major indirect channel. In structural heart disease, adoption depends heavily on clinical evidence. Peer-reviewed data, congress presentations, and investigator-led studies shape physician behavior long before a hospital changes its purchasing pattern. This channel matters because it reduces clinical uncertainty. It also supports premium positioning when the product is tied to outcomes, procedural success, or reduced complications. For an academic paper, this channel is useful because it shows how medical device companies sell through evidence, not just through price.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eScientific congresses help move data from research into clinical practice.\u003c\/li\u003e\n \u003cli\u003ePublications support physician trust and hospital committee review.\u003c\/li\u003e\n \u003cli\u003eTraining content helps convert evidence into routine use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReimbursement and access programs\u003c\/strong\u003e are another essential channel because payment determines adoption. In hospital-based care, a product can have strong clinical value and still face slow uptake if reimbursement is unclear. Edwards Lifesciences Corporation supports coding, coverage, and access education so providers can navigate the payment process. This channel is important because it reduces administrative barriers for hospitals and helps patients reach treatment. In practical terms, access programs connect the product's clinical value to the economics of care delivery.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAccess function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer affected\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage support\u003c\/td\u003e\n\u003ctd\u003ePayers and hospitals\u003c\/td\u003e\n\u003ctd\u003eImproves the chance that procedures can be reimbursed\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoding guidance\u003c\/td\u003e\n\u003ctd\u003eBilling teams\u003c\/td\u003e\n\u003ctd\u003eReduces claims friction and administrative delays\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access education\u003c\/td\u003e\n\u003ctd\u003ePatients and care coordinators\u003c\/td\u003e\n\u003ctd\u003eHelps move eligible patients into treatment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercial organization\u003c\/strong\u003e is the operating layer that connects all channels across regions. Edwards Lifesciences Corporation sells in multiple markets, so it needs local teams that understand regulation, language, reimbursement, hospital systems, and physician training patterns. A global commercial structure matters because device adoption is local even when the brand is global. Each market can have different approval pathways, different payer rules, and different hospital buying processes. That makes region-specific execution a core part of the channel model.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRegional teams adapt sales messages to local clinical practice.\u003c\/li\u003e\n \u003cli\u003eLocal market access teams handle reimbursement differences by country.\u003c\/li\u003e\n \u003cli\u003eClinical specialists support training and adoption after launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe channel model depends on coordination between sales, medical affairs, reimbursement, and training. In a medical device business like Edwards Lifesciences Corporation, the channel is not only a route to market. It is part of the product's clinical adoption process, because hospitals, physicians, and payers all shape whether the device is used.\u003c\/p\u003e\n\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eEdwards Lifesciences Corporation serves hospitals, specialists, patients, and payers in structural heart care, with demand shaped by valve disease prevalence, procedure volume, and reimbursement access.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eWhat they buy or decide\u003c\/th\u003e\n\u003cth\u003eWhy they matter to Edwards Lifesciences Corporation\u003c\/th\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and health systems\u003c\/td\u003e\n\u003ctd\u003eDevices, procedure support, training, and purchasing contracts\u003c\/td\u003e\n \u003ctd\u003eThey control procedure access, capital planning, and large-volume purchasing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterventional cardiologists\u003c\/td\u003e\n\u003ctd\u003eTranscatheter valve therapies and clinical evidence\u003c\/td\u003e\n \u003ctd\u003eThey choose therapies for catheter-based valve procedures\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac surgeons and heart teams\u003c\/td\u003e\n\u003ctd\u003eSurgical and transcatheter treatment options\u003c\/td\u003e\n \u003ctd\u003eThey determine treatment pathways for complex valve disease\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with aortic, mitral, and tricuspid disease\u003c\/td\u003e\n \u003ctd\u003eTreatment outcomes, recovery time, durability, and quality of life\u003c\/td\u003e\n \u003ctd\u003eThey create clinical demand and influence treatment acceptance\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and coverage decision makers\u003c\/td\u003e\n\u003ctd\u003eEvidence on clinical benefit, total cost, and coverage criteria\u003c\/td\u003e\n \u003ctd\u003eThey determine reimbursement and access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e1.5 million\u003c\/strong\u003e people in the United States are commonly cited as having aortic stenosis, and severe symptomatic disease is the core population for transcatheter and surgical valve replacement demand.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e4.0 million\u003c\/strong\u003e people in the United States are commonly cited as having mitral regurgitation, which supports a broader long-term addressable pool for transcatheter mitral therapies and surgical repair pathways.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e1.6 million\u003c\/strong\u003e people in the United States are commonly cited as having tricuspid regurgitation, which matters because tricuspid disease has historically been undertreated and is a growth area for structural heart care.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and health systems\u003c\/strong\u003e are the main institutional buyers. They evaluate procedure outcomes, length of stay, staffing needs, catheterization lab use, operating room time, and total episode cost. For Edwards Lifesciences Corporation, this segment matters because a hospital often decides whether a valve therapy becomes a standard pathway or remains a niche option. Large academic centers and integrated health systems also influence referral patterns, physician training, and adoption of new devices across multiple sites.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAcademic medical centers\u003c\/li\u003e\n\u003cli\u003eLarge integrated delivery networks\u003c\/li\u003e\n\u003cli\u003eCommunity hospitals with structural heart programs\u003c\/li\u003e\n \u003cli\u003eSpecialty cardiovascular centers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInterventional cardiologists\u003c\/strong\u003e are key clinical decision makers for catheter-based therapies. They assess anatomy, procedural risk, and device fit, then choose between transcatheter and surgical options. Their demand is shaped by imaging quality, procedural ease, learning curve, and evidence from randomized trials and registries. This segment matters because adoption can spread quickly once physicians trust the device performance and the procedure workflow fits their lab.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eStructural heart interventionalists\u003c\/li\u003e\n\u003cli\u003eGeneral interventional cardiologists with valve program involvement\u003c\/li\u003e\n \u003cli\u003eElectrophysiology-adjacent cath lab physicians in referral hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiac surgeons and heart teams\u003c\/strong\u003e are central in treatment selection, especially for patients who may benefit from surgery, transcatheter therapy, or staged care. A heart team usually includes interventional cardiology, cardiac surgery, imaging, anesthesia, and sometimes geriatrics or primary care. This segment matters because many valve decisions are not made by one physician alone. The team approach reduces single-physician bias and links device adoption to institutional protocols.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCardiac surgeons\u003c\/li\u003e\n\u003cli\u003eValve clinic physicians\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary heart teams\u003c\/li\u003e\n\u003cli\u003eImaging specialists\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatients with aortic, mitral, and tricuspid disease\u003c\/strong\u003e are the clinical demand base. They care most about symptom relief, survival, recovery time, repeat procedures, and quality of life. Many older patients also weigh hospital stay length and return to normal activity. This segment matters because patient acceptance affects procedure timing, referral completion, and demand for less invasive options. In structural heart care, patients often enter the market through symptoms, echo findings, or referral from a primary doctor.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAortic stenosis patients\u003c\/li\u003e\n\u003cli\u003eMitral regurgitation patients\u003c\/li\u003e\n\u003cli\u003eTricuspid regurgitation patients\u003c\/li\u003e\n\u003cli\u003eOlder adults with multiple comorbidities\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers and coverage decision makers\u003c\/strong\u003e include Medicare, Medicare Advantage plans, commercial insurers, and hospital value analysis teams. They focus on clinical evidence, hospital utilization, readmissions, and total cost of care. This segment matters because even strong clinical demand can stall if coverage is limited, prior authorization is slow, or reimbursement does not support adoption. For Edwards Lifesciences Corporation, payer acceptance affects where devices are used, how fast new indications spread, and whether hospitals can scale programs profitably.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eDecision maker\u003c\/th\u003e\n\u003cth\u003eTypical focus\u003c\/th\u003e\n\u003cth\u003eEffect on Edwards Lifesciences Corporation\u003c\/th\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003eCoverage policy and reimbursement structure\u003c\/td\u003e\n \u003ctd\u003eBroad access for older patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial insurers\u003c\/td\u003e\n\u003ctd\u003eMedical necessity and prior authorization\u003c\/td\u003e\n \u003ctd\u003eImpacts speed of adoption in working-age and retiree populations\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital value analysis committees\u003c\/td\u003e\n\u003ctd\u003eCost, outcomes, and supplier selection\u003c\/td\u003e\n\u003ctd\u003eInfluences purchasing and standardization\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated delivery networks\u003c\/td\u003e\n\u003ctd\u003eEpisode cost and care pathway efficiency\u003c\/td\u003e\n \u003ctd\u003eCan accelerate or slow multi-site adoption\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese customer segments are not independent. Hospitals buy the devices, physicians choose them, patients receive them, and payers decide whether the treatment is affordable and covered. That is why Edwards Lifesciences Corporation sells into a medical ecosystem, not just a single buyer.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost structure item\u003c\/td\u003e\n\u003ctd\u003eLatest disclosed treatment\u003c\/td\u003e\n\u003ctd\u003eNumeric detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D investment\u003c\/td\u003e\n\u003ctd\u003eResearch and development expense\u003c\/td\u003e\n\u003ctd\u003eNot separately provided here\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A and access spending\u003c\/td\u003e\n\u003ctd\u003eSelling, general and administrative expense\u003c\/td\u003e\n \u003ctd\u003eNot separately provided here\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial costs\u003c\/td\u003e\n\u003ctd\u003eIncluded in research and development expense\u003c\/td\u003e\n \u003ctd\u003eNot separately provided here\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and quality expenses\u003c\/td\u003e\n\u003ctd\u003eCost of sales and production overhead\u003c\/td\u003e\n\u003ctd\u003eNot separately provided here\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal and regulatory costs\u003c\/td\u003e\n\u003ctd\u003eIncluded in operating expenses\u003c\/td\u003e\n\u003ctd\u003eNot separately provided here\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D investment:\u003c\/strong\u003e not separately broken out into clinical programs, device development, or platform work in the table above. For a medical technology company, R\u0026amp;D is usually the largest variable cost pool after manufacturing, but the relevant disclosed dollar amount is not included here.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expense\u003c\/li\u003e\n\u003cli\u003eClinical development expense\u003c\/li\u003e\n\u003cli\u003eProduct design and testing expense\u003c\/li\u003e\n\u003cli\u003eRegulatory submission expense\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and access spending:\u003c\/strong\u003e not separately disclosed here. In this business model, access spending typically sits inside SG\u0026amp;A because it covers sales force, market access, reimbursement support, and hospital account support.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSelling expense\u003c\/li\u003e\n\u003cli\u003eMarket access expense\u003c\/li\u003e\n\u003cli\u003eAdministrative expense\u003c\/li\u003e\n\u003cli\u003ePhysician and hospital education expense\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trial costs:\u003c\/strong\u003e not separated from R\u0026amp;D in the figures shown here. These costs normally include investigator payments, site management, data handling, and patient follow-up.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and quality expenses:\u003c\/strong\u003e not separately disclosed here. In a device company, these costs usually include plant labor, materials, cleanroom operations, sterilization, inspection, validation, and complaint handling.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMaterials\u003c\/li\u003e\n\u003cli\u003eDirect labor\u003c\/li\u003e\n\u003cli\u003eQuality control\u003c\/li\u003e\n\u003cli\u003eValidation and sterilization\u003c\/li\u003e\n\u003cli\u003eWarranty and field actions\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLegal and regulatory costs:\u003c\/strong\u003e not separately disclosed here. These costs typically include FDA-related submissions, compliance systems, patent matters, litigation, and product liability reserves.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost driver\u003c\/td\u003e\n\u003ctd\u003eCash outflow type\u003c\/td\u003e\n\u003ctd\u003eBalance-sheet or income-statement effect\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003eExpense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003eExpense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003eExpense inside R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and quality\u003c\/td\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003eCost of sales and operating expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal and regulatory\u003c\/td\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003eOperating expense and reserves\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCost structure concentration:\u003c\/strong\u003e this business model is research-heavy, sales-heavy, and regulation-heavy. That means the cost base is driven more by ongoing product development, clinical evidence generation, physician adoption, and manufacturing quality than by one-time production scale alone.\u003c\/p\u003e\u003ch2\u003eEdwards Lifesciences Corporation - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEdwards Lifesciences Corporation\u003c\/strong\u003e does not publicly break out exact dollar revenue for each structural heart product line in a way that lets you isolate every stream cleanly. The core revenue model still comes from three device families and two recurring channels: transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, surgical heart valves, international structural heart sales, and procedure-linked sales of disposable and catheter-based products.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHow revenue is generated\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eRevenue timing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAVR device sales\u003c\/td\u003e\n\u003ctd\u003eSales of transcatheter aortic valve replacement systems used in aortic stenosis procedures\u003c\/td\u003e\n \u003ctd\u003eAt the time of hospital purchase and implant\u003c\/td\u003e\n \u003ctd\u003eMain profit engine and the largest structural heart revenue driver\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTMTT device sales\u003c\/td\u003e\n\u003ctd\u003eSales of transcatheter mitral and tricuspid repair and replacement devices\u003c\/td\u003e\n \u003ctd\u003eAt the time of hospital purchase and implant\u003c\/td\u003e\n \u003ctd\u003eEarlier-stage growth stream tied to category expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical heart valve sales\u003c\/td\u003e\n\u003ctd\u003eSales of surgical replacement valves and related products\u003c\/td\u003e\n \u003ctd\u003eAt the time of hospital purchase and surgery\u003c\/td\u003e\n \u003ctd\u003eMore mature revenue line with lower growth but strong clinical relevance\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational structural heart sales\u003c\/td\u003e\n\u003ctd\u003eSales outside the United States across Europe, Asia-Pacific, Latin America, and other regions\u003c\/td\u003e\n \u003ctd\u003eAt the time of local distributor or hospital purchase\u003c\/td\u003e\n \u003ctd\u003eReduces dependence on the U.S. market and broadens procedure volume\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring procedure-driven product revenue\u003c\/td\u003e\n \u003ctd\u003eSales linked to repeat procedures, including disposables, accessories, and catheter-based systems\u003c\/td\u003e\n \u003ctd\u003eEvery procedure\u003c\/td\u003e\n\u003ctd\u003eCreates repeat demand and improves visibility into future revenue\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eTAVR device sales\u003c\/strong\u003e are the central revenue stream in Edwards Lifesciences Corporation's business model. TAVR is a one-time implant procedure, so every valve sale is tied to a hospital case. That makes revenue depend on procedure volume, hospital adoption, clinical guideline support, and reimbursement coverage. This stream matters because it is the most established and commercially mature part of the company's structural heart franchise. In a Business Model Canvas, this is the highest-value product revenue block and the main source of scale.\u003c\/p\u003e\n\n\u003cp\u003eThe economics of TAVR are simple: one procedure, one valve sale, one revenue event. The company's revenue growth here depends on patient eligibility expansion, physician preference, and competition in the aortic valve market. Because TAVR is used in high-acuity cardiac care, demand is tied to diagnosis rates, referral patterns, and hospital capacity rather than consumer spending.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue is procedure-based, not subscription-based.\u003c\/li\u003e\n \u003cli\u003eDemand depends on the number of eligible patients treated.\u003c\/li\u003e\n \u003cli\u003eHospitals are the direct buyers, not patients.\u003c\/li\u003e\n \u003cli\u003ePrice realization depends on reimbursement and competitive positioning.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTMTT device sales\u003c\/strong\u003e are the growth option in the revenue model. TMTT means transcatheter mitral and tricuspid therapies, which target two valves that are harder to treat than the aortic valve. These products are earlier in adoption than TAVR, so they contribute less mature but more expandable revenue. The business value here is category creation: each approved indication can open new procedural volume and new hospital demand.\u003c\/p\u003e\n\n\u003cp\u003eThis stream is important because it reduces reliance on a single market. It also changes the revenue mix over time by adding products aimed at structural heart diseases that have historically been under-treated. For academic analysis, this stream shows how Edwards Lifesciences Corporation uses clinical innovation to build future revenue rather than relying only on existing sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSurgical heart valve sales\u003c\/strong\u003e give Edwards Lifesciences Corporation a second revenue base alongside transcatheter products. These sales come from traditional open-heart surgery markets and remain relevant even as minimally invasive procedures grow. The stream matters because it gives the company exposure to both surgical and catheter-based care pathways. That diversifies revenue and supports relationships with cardiac surgeons and hospitals.\u003c\/p\u003e\n\n\u003cp\u003eThis line is usually more mature than TAVR and TMTT, which means it tends to serve as a stabilizer in the product mix. In strategic terms, that lowers dependence on a single procedure type. For a student writing a case study, this is a useful example of how an incumbent medtech company protects revenue while shifting toward newer technologies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational structural heart sales\u003c\/strong\u003e are the geographic layer of the revenue model. Edwards Lifesciences Corporation sells structural heart products outside the United States, and those markets matter because procedure adoption differs by country, reimbursement system, and clinical practice. International revenue supports diversification, but it also brings currency exposure, regulatory complexity, and uneven hospital access.\u003c\/p\u003e\n\n\u003cp\u003eThis stream matters because it can widen the addressable market without changing the underlying product platform. It also helps the company avoid relying too heavily on one health system. In Business Model Canvas terms, geography is part of the revenue capture mechanism, not just the delivery channel.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMain buyer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue trigger\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eStrategic role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAVR device sales\u003c\/td\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eAortic valve procedure\u003c\/td\u003e\n\u003ctd\u003eCore cash generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTMTT device sales\u003c\/td\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eMitral or tricuspid procedure\u003c\/td\u003e\n\u003ctd\u003eFuture growth driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical heart valve sales\u003c\/td\u003e\n\u003ctd\u003eHospitals and cardiac surgery centers\u003c\/td\u003e\n\u003ctd\u003eOpen-heart valve surgery\u003c\/td\u003e\n\u003ctd\u003ePortfolio stabilizer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational structural heart sales\u003c\/td\u003e\n\u003ctd\u003eHospitals, distributors, and health systems\u003c\/td\u003e\n \u003ctd\u003eCountry-specific adoption and reimbursement\u003c\/td\u003e\n \u003ctd\u003eGeographic diversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring procedure-driven product revenue\u003c\/td\u003e\n \u003ctd\u003eHospitals and procedural labs\u003c\/td\u003e\n\u003ctd\u003eEach repeat procedure\u003c\/td\u003e\n\u003ctd\u003ePredictable repeat demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring procedure-driven product revenue\u003c\/strong\u003e is what makes the model more predictable than a single one-time device sale. Every implantation or repair procedure can also generate sales of supporting products, accessories, delivery systems, and other procedure-linked items. This kind of revenue is important because it follows clinical activity, so it usually rises when procedure volumes rise.\u003c\/p\u003e\n\n\u003cp\u003eThis stream improves revenue visibility. When a company sells products that are needed every time a procedure happens, it creates repeat demand from the same hospitals and clinical teams. That does not remove competition, but it does make the business less dependent on one-off purchases. In financial analysis, this is one reason recurring procedure-driven revenue is often viewed as higher quality than purely episodic sales.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEach procedure can create multiple sales events.\u003c\/li\u003e\n \u003cli\u003eRepeat clinical use supports recurring demand.\u003c\/li\u003e\n \u003cli\u003eRevenue visibility is stronger than for one-time equipment sales.\u003c\/li\u003e\n \u003cli\u003eGrowth tracks procedure volume more than consumer demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRevenue concentration\u003c\/strong\u003e in structural heart products means changes in procedure volume, reimbursement, and competitive pressure can move sales quickly. That makes the mix between TAVR, TMTT, surgical valves, and international sales important in financial modeling. A stronger mix of recurring and multi-region revenue usually supports steadier performance than dependence on one product in one country.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEdwards Lifesciences Corporation\u003c\/strong\u003e builds revenue mainly from implanted devices and procedure-linked repeat sales, not from software, advertising, or consumer purchases. That makes the company's revenue model highly clinical, hospital-based, and dependent on physician adoption, regulatory approval, and reimbursement access.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601596608661,"sku":"ew-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ew-business-model-canvas.png?v=1740169074","url":"https:\/\/dcf-model.com\/products\/ew-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}